Evidence map›Paper›PMID 25903134›Full record

ArticleThe Journal of biological chemistry2015

Factor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising "Hot-Spot" Lysine Residues.

Maartje van den Biggelaar, Jesper J Madsen, Johan H Faber, Marleen G Zuurveld, Carmen van der Zwaan, Ole H Olsen, Henning R Stennicke, Koen Mertens, Alexander B Meijer

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. α1-Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Maartje van den BiggelaarFrom the Department of Plasma Proteins, Sanquin Blood Supply Foundation, 1066 CX Amsterdam, The Netherlands, m.vandenbiggelaar@sanquin.nl.
Jesper J MadsenGlobal Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark, and.
Johan H FaberGlobal Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark, and.
Marleen G ZuurveldFrom the Department of Plasma Proteins, Sanquin Blood Supply Foundation, 1066 CX Amsterdam, The Netherlands.
Carmen van der ZwaanFrom the Department of Plasma Proteins, Sanquin Blood Supply Foundation, 1066 CX Amsterdam, The Netherlands.
Ole H OlsenGlobal Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark, and.
Henning R StennickeGlobal Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark, and.
Koen MertensFrom the Department of Plasma Proteins, Sanquin Blood Supply Foundation, 1066 CX Amsterdam, The Netherlands, the Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TC Utrecht, The Netherlands.
Alexander B MeijerFrom the Department of Plasma Proteins, Sanquin Blood Supply Foundation, 1066 CX Amsterdam, The Netherlands, the Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TC Utrecht, The Netherlands.
Novo Nordisk (Denmark) · DKSanquin · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysine residues are implicated in driving the ligand binding to the LDL receptor family. However, it has remained unclear how specificity is regulated. Using coagulation factor VIII as a model ligand, we now study the contribution of individual lysine residues in the interaction with the largest member of the LDL receptor family, low-density lipoprotein receptor-related protein (LRP1). Using hydrogen-deuterium exchange mass spectrometry (HDX-MS) and SPR interaction analysis on a library of lysine replacement variants as two independent approaches, we demonstrate that the interaction between factor VIII (FVIII) and LRP1 occurs over an extended surface containing multiple lysine residues. None of the individual lysine residues account completely for LRP1 binding, suggesting an additive binding model. Together with structural docking studies, our data suggest that FVIII interacts with LRP1 via an extended surface of multiple lysine residues that starts at the bottom of the C1 domain and winds around the FVIII molecule.

Indexed as

Amino Acid MotifsAmino Acid SequenceBinding SitesCrystallography, X-RayDeuterium Exchange MeasurementEndocytosisFactor VIIIHumansLipoproteins, LDLLow Density Lipoprotein Receptor-Related Protein-1LysineMass SpectrometryMolecular Sequence DataProtein BindingProtein Structure, TertiaryFactor VIIILipoproteins, LDLLow Density Lipoprotein Receptor-Related Protein-1LRP1 protein, humanLysinecoagulation factorfactor VIII (FVIII)hydrogen-deuterium exchangehydrogen exchange mass spectrometrylow-density lipoprotein receptor-related protein 1protein-protein interactionreceptorsurface plasmon resonance (SPR)

Identifiers

PMID25903134
PMCPMC4505400
OpenAlexW2081398430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.